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List of abbreviations: 
CD: Crohn’s disease; CDAI: Crohn’s disease activity index; CHF: Swiss francs; CI: 
confidence interval; EIM: Extra-intestinal manifestations; IBD: inflammatory bowel disease; 
ICER: Incremental cost-effectiveness ratio; PSA: Probabilistic sensitivity analysis; QALY: 
Quality-adjusted life years; RCT: Randomised controlled trials; SD: Standard deviation; SE: 
Standard error; SIBDCS: Swiss IBD cohort study; WTP: Willingness-to-pay threshold 
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ABSTRACT 
 
Background and Aims 
We evaluated the cost-effectiveness of early (≤2 years after diagnosis) compared to late or no 
biologic initiation (starting biologics >2 years after diagnosis or no biologic use) for adults with 
Crohn’s disease in Switzerland. 
 
Methods 
We developed a Markov cohort model over the patient’s lifetime from the health system and 
societal perspectives. Transition probabilities, quality of life, and costs were estimated using 
real world data. Propensity score matching was used to ensure comparability between patients 
in the early (intervention) and late/no (comparator) biologic initiation strategies. The 
incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained is 
reported in Swiss francs (CHF). Sensitivity and scenario analyses were performed. 
 
Results 
Total costs and QALYs were higher for the intervention (CHF384,607; 16.84 QALYs) 
compared to comparator (CHF340,800; 16.75 QALYs) strategy, resulting in high ICERs 
(health system: CHF887,450 per QALY; societal: CHF449,130 per QALY). Assuming a 
threshold of CHF100,000 per QALY, in probabilistic sensitivity analysis the intervention 
strategy had a 0.1 and 0.25 probability of being cost-effective from the health system and 
societal perspectives, respectively. In addition, ICERs improved when we assumed a 30% 
reduction in biologic prices (health system: CHF134,502 per QALY; societal: intervention 
dominant). 
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Conclusions 
Early biologic use was not cost-effective considering a threshold of CHF100,000 per QALY 
compared to late/no biologic use. However, early identification of patients likely to need 
biologics and future drug price reductions through increased availability of biosimilars may 
improve the cost-effectiveness of an early treatment approach.  
 
Keywords: Crohn’s Disease; Cost-Effectiveness; Early Biologic Initiation
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INTRODUCTION 
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) causing inflammation in 
the gastrointestinal tract. It is characterised by active and remitting phases, severe symptoms, 
and extra-intestinal complications. Patients are at risk of developing bowel complications, 
including strictures and fistulae, and often require surgical interventions and long-term 
pharmaceutical treatment to manage the disease1. The prevalence of CD varies significantly in 
Europe with estimates between 1.5 and 213 per 100,000 persons2. In Switzerland, uptake of 
novel biologic treatments was associated with a marked increase in health care expenditures 
placing significant financial pressure on the health system3. The changing treatment landscape 
and a rising prevalence4 mark an important opportunity to identify clinically- and cost-efficient 
treatment strategies. 
 
The primary aim of CD clinical management is to induce and maintain remission. 
Pharmaceutical treatments include aminosalicylates, corticosteroids, immunosuppressants, and 
biologic agents. The current standard of care involves stepping-up therapy and reserving more 
aggressive treatments, such as biologic agents, for patients with severe and refractory disease5. 
Treatment with biologic agents helped increase remission rates and reduce the need for surgery 
and hospitalisation, sparking debate about the optimal timing of treatment initiation6 7. Some 
have advocated for early biologic treatment, within 2 years of diagnosis, with the hope that this 
would shift disease management from symptom control towards long-term mucosal healing and 
modification of the disease course8-10. However, few studies have evaluated the long-term 
clinical efficacy or cost-effectiveness of this approach11 12.  
 
A randomised controlled trial (RCT) found increased corticosteroid-free remission and reduced 
surgical resection rates after one year in patients receiving early treatment with 
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immunosuppressants and biologic agents compared to the standard step-up approach6. Based 
on this trial, early combination therapy was reported to be cost-effective compared to the 
standard of care from the Italian health system perspective over five years13. These studies are 
limited in scope, however, since only induction of remission was evaluated and follow-up was 
short. Another analysis, using seven years of follow-up data from a retrospective cohort study 
in Canada14, demonstrated that early treatment with biologic agents was cost-saving and 
improved health outcomes over patients’ lifetime due to high response rates15. However, several 
RCTs and observational studies found conflicting evidence, suggesting no health gains from 
early biologic and combination therapy12 16. Therefore, currently available evidence need to be 
validated in order to inform health care planning and decision-making in Switzerland.  
 
This study aimed to evaluate the cost-effectiveness of early initiation (≤2 years after diagnosis) 
of biologic treatment compared to late or no biologic use (starting biologic therapy >2 years 
after diagnosis or continuing non-biologic therapy) for CD patients using real world data in 
Switzerland. 
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MATERIALS AND METHODS 
Overview of modelling approach 
A Markov cohort model was developed to compare the cost-effectiveness of early biologic 
treatment (intervention) to late/no biologic treatment (comparator) for recently diagnosed adult 
(≥18 years) CD patients. The analysis was conducted from the Swiss health system perspective, 
considering all direct health care costs irrespective of payer (cantons/regions, health insurers, 
and patients’ out-of-pocket co-payments), and a societal perspective, including direct and 
indirect costs associated with productivity losses from work absenteeism. The model was run 
over the patients’ lifetime based on the mean age at diagnosis and life expectancy in 
Switzerland17. The model was parameterised using transition probabilities, costs and utilities 
estimated from the Swiss IBD Cohort Study (SIBDCS) and insurance claims data. Costs and 
utilities occurring after the first year were discounted by 3%. One-way and probabilistic 
sensitivity analysis (PSA) were performed to evaluate the impact of parameter uncertainty on 
results. The model was built and analysed using TreeAge Pro 2018 (Williamstown, MA). 
Statistical analyses to derive parameters for the model were performed in Stata Version 15 
(College Station, TX). 
 
The primary outcome of the model was the incremental cost-effectiveness ratio (ICER) per 
quality-adjusted life year (QALY) gained, reported in Swiss francs (CHF). The ICER measures 
the additional costs required to achieve one unit of additional effect, calculated by dividing the 
difference in costs by the difference in effects between the two strategies. Effects are expressed 
as QALYs reflecting individuals’ length of life and health-related quality of life18. The ICER is 
compared to a willingness-to-pay (WTP) threshold, which captures the assumed value of an 
additional QALY, to make conclusions about cost-effectiveness18. There is no commonly 
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accepted WTP threshold in Switzerland; therefore, based on previous literature19-21, we 
tentatively used a threshold of CHF100,000 (€89,500) per QALY.  
 
Data source and patient population 
The SIBDCS is a prospective, national cohort recruiting adult and paediatric IBD patients from 
academic and non-academic centres across Switzerland. The cohort is described in detail 
elsewhere22. For this study, we conducted a retrospective analysis of annual patient-level data 
extracted from questionnaires completed by patients and their treating physicians between 2006 
and 2018. Physician-reported data included information on patient demographics, disease and 
treatment characteristics, and health care utilisation. Patient-reported data included outpatient 
consultation visits, days of work missed due to IBD, and health-related quality of life. 
 
We used propensity score matching to ensure patients in the intervention and comparator groups 
were similar based on baseline characteristics that might influence treatment assignment and 
health outcomes23. This reduced the effects of selection bias associated with observational data. 
We used a logistic regression model, adjusting for treatment group and key characteristics 
measured at diagnosis or enrolment, to estimate the probability (propensity score) of receiving 
the intervention. Methods and results of the propensity score model are described in 
Supplementary Files Table S1.  
 
In total, 411 patients were matched in the intervention (N=230) and comparator (N=181) 
groups; 50% were female with a mean age at diagnosis of 33 years (Supplementary Files Table 
S2). Key clinical characteristics such as age at diagnosis, disease location, and disease 
complications were balanced between the groups, resulting in significant overlap in propensity 
scores after matching (Supplementary Files Figure S1). In the comparator group, 51% of 
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patients received a biologic treatment more than two years after diagnosis, while the remaining 
49% did not receive any biologics during follow-up (see Supplementary Files Table S2 for 
further descriptive characteristics and a comparison of the early compared to no biologic 
treatment groups). Biologic treatments included all those approved in Switzerland in 2018: 
infliximab, adalimumab, golimumab, certolizumab pegol, vedolizumab, and ustekinumab. All 
subsequent analyses including estimation of health state risks, costs, and utilities, were 
performed using the matched sample. 
 
Model structure and assumptions 
The Markov model reflects patients moving between active and remitting phases of the disease 
in annual periods (cycles). Costs and QALYs in the first and last cycle were multiplied by 0.5 
(half-cycle correction) to adjust for overestimation from annual state transitions. Active disease 
states were split into four mutually exclusive and exhaustive groups: disease flares with no 
complications (disease flares), fistula, stricture, and intestinal resection surgery (surgery); 
defined in Table 1.  
 
[TABLE 1 HERE] 
 
Patients entered the model at diagnosis in the disease flares state based on data from the 
SIBDCS. After each cycle of the model patients transition to other active health states, 
remission, or death (Figure 1). Patients could remain in the previous health state over multiple 
cycles of the model or transition to death from any state where they then remain. Patients are 
assumed to be in one health state at a time.  
 
[FIGURE 1 HERE] 
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Model parameterisation  
Transition probabilities 
Parametric time-to-event analysis was used to estimate time-to-event curves for each health 
state, from which time-varying annual transition probabilities were calculated (Supplementary 
Files Figure S3). Separate time-to-event curves were estimated for the intervention and 
comparator groups allowing for time-dependent treatment effects. The analysis period was 
defined from the time of diagnosis to event/failure or administrative censoring. Events were 
observed prospectively from enrolment in the SIBDCS. Due to the recurrent nature of events, 
unconditional shared frailty models were used to predict the risks of disease flares, fistula, 
stricture, and remission. These models accounted for unobserved heterogeneity and dependence 
between event failures for each individual24 25. Single event models were used to parameterise 
the risk of surgery since repeated event models did not fit the data well due to a paucity of 
multiple surgeries in this sample.  
 
Parametric models were used to extrapolate time-to-event curves over patients’ lifetime 
(Supplementary Files Table S4). Models tested included the Weibull, lognormal, loglogistic, 
Gompertz, and Exponential distributions. Appropriate models were chosen based on visual 
inspection of the fit of predicted time-to-event curves on non-parametric Kaplan-Meier curves 
(Supplementary Files Figure S2) and the Akaike Information Criteria (Supplementary Files 
Table S3).  
 
Transition probabilities did not consider disease history thereby assuming that the probability 
of recurrent events was independent of previous health states (Supplementary Files Table S5). 
This assumption was made due to a small sample to parameterise conditional probabilities and 
increased model complexity required to capture disease history. Correlations between events 
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were not considered, thus events were assumed to occur independently. The complement of 
probabilities in each cycle was used to parametrise the probability of remaining in the same 
health state such that transition probabilities summed to 1. 
 
Mortality rates 
Mortality rates were obtained from the general Swiss population in 2017 in 10-year age 
groups26 (Supplementary Files Table S6). These were increased by 39% to reflect the CD-
specific mortality risk using evidence from a meta-analysis of population-based studies across 
Europe and the USA27.  
 
Direct and indirect costs 
Methods used to derive unit costs for health care utilisation are described in detail elsewhere3. 
In brief, unit costs for IBD-related inpatient and outpatient events recorded in the SIBDCS were 
estimated from reimbursement claims data obtained from the Helsana Group (see 
Supplementary Files Table S8 for a full list of procedures considered). This is a leading health 
insurance company in Switzerland providing statutory health insurance to 15% of the 
population4. Costs estimated from this dataset are based on national reimbursement tariffs, 
which are standardised across Switzerland (TARMED28 in the outpatient sector and Swiss 
diagnosis-related groups29 in the inpatient sector) and adjust for regional variations in costs. 
Unit cost estimates were used to cost-weight the health care utilisation reported in the SIBDCS. 
Pharmaceutical costs were derived from public price lists30 using recommended dosing 
schedules31. All costs were inflated to 2017 values using the consumer price index in 
Switzerland32. Indirect costs were calculated using 2017 national median salaries in 
Switzerland33 and annual patient-reported days absent from work recorded in the SIBDCS. 
Swiss national labour participation rates in 2017 were used to adjust indirect costs by age34 
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(Supplementary Files Table S7). Costs are reported in CHF and converted to euros (€) using 
the average exchange rate in 2017 of CHF1 = €0.8935. 
 
For the cost-effectiveness model, mean annual per patient costs were estimated from 
generalised linear regression models with a gamma distribution and log link function. We used 
separate regression models for each treatment group including the presence of all health states 
and disease duration as covariates. Mean direct costs for the first eight years after diagnosis 
were predicted for each health state (Table 2). This allowed costs to vary over time due to 
patients switching treatments. After eight years, costs in each health state were held constant 
for the remainder of the time that the model was run, assuming that a stable treatment pattern 
was reached and that drug prices remained constant over time. Mean annual per patient indirect 
costs were estimated for active disease states combined and remission, and were assumed to 
remain constant over time (Table 3). 
 
[TABLE 2 HERE] 
 
Quality-adjusted life years 
Patient-reported quality of life was measured annually using the Short Form 36 (SF-36) 
questionnaire in the SIBDCS36. To generate utilities, patients’ responses to each item in the SF-
36 were mapped to the SF-6D using published algorithms36. Utility valuations from the SF-6D 
were obtained from a sample of the general population in the UK37.  
 
Mean utilities (Table 3) for each health state were estimated from a linear regression model 
adjusting for treatment group, health state, disease duration, and the gap (in years) between the 
date of SF-36 record and the health event (used to adjust for the effects of any delay between 
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the measurement of patient-reported quality of life and the physician-reported health event in 
the SIBDCS). Utilities were multiplied by patients’ length of life per model cycle to calculate 
QALYs for each health state18. Utilities were assumed to be the same for a given health state 
irrespective of treatment group and were held constant over time. Thus, any differences in 
QALYs reflect variations in the risks of health outcomes between the treatment groups.  
 
One-way and probabilistic sensitivity analysis 
In one-way sensitivity analysis all parameters (transition probabilities, costs, and utilities) were 
varied independently using the 95% confidence intervals (CI) (Table 3). Standard errors (SE) 
for transition probabilities and costs were assumed to be 20% of the mean. The mean annual 
probability for each health state was calculated by averaging annual transition probabilities over 
the time horizon of the model. This ensured that transition probabilities did not sum to greater 
than 1 when varied over wide ranges. For indirect costs, ±20% of the mean was used because 
the lower bound of the 95% CIs was negative.  
 
In PSA, joint parameter uncertainty was assessed using 10,000 Monte Carlo simulations. 
Parameters were varied around the mean and SEs using recommended distributions18 (Table 3). 
Specifically, beta distributions were used for utilities and transition probabilities to ensure that 
sampled values were bounded between zero and one. Gamma distributions were used for costs 
to account for its non-negative and skewed properties. Transition probabilities were normalised 
so that they summed to one when varied over wide ranges. 
 
[TABLE 3 HERE] 
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Scenario and subgroup analyses 
Several scenarios were analysed to assess variations in the base case results based on 
methodological assumptions. This included choosing alternative discount rates (0%, 2% and 
5%), shorter time horizons (1 year and 10 years), varying utility estimates using values from 
published literature, and using a fixed overall mean direct cost per health state. In addition, we 
evaluated the impact of a 30% reduction on the price of biologic agents based on the estimated 
price difference between biosimilars and branded biologics in the EU38.  
 
We also tested the influence of alternative derivations for transition probabilities. First, to 
account for disease history, we generated subgroup-specific transition probabilities from 
patients who experienced a previous remission or active event (Supplementary Files Table S9 
and Table S10). Second, we used the complement of all probabilities in each cycle to 
parameterise the probability of remission (Supplementary Files Table S11). Finally, we derived 
transition probabilities from Kaplan-Meier curves (instead of parametric models) over a 10 year 
time horizon (Supplementary Files Table S12).  
 
A subgroup analysis was performed comparing health outcomes for the subset of the population 
followed in the SIBDCS who were known to receive biologic therapies. In the base case 
analysis, we evaluated the balance between treatment groups extensively, including comparing 
descriptive characteristics of the non-biologic users to early biologic users (Supplementary 
Files “Descriptive statistics”). Although we did not find any indication of selection bias between 
the treatment groups after the propensity score matching, we conducted this subgroup analysis 
in order to address the possibility that non-biologic users might have a different, and potentially 
milder, disease course compared to patients who required biologic treatment. This subgroup 
analysis assumed prior knowledge of which patients would be likely to require biologic 
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therapies during the course of their disease. In this analysis, we excluded patients who did not 
receive at least one dose of any biologic therapy during follow-up in the SIBDCS. The 
remaining patients were stratified into early (≤2 years after diagnosis) and late (>2 years after 
diagnosis) biologic initiation groups. Propensity score matching was used to ensure that patients 
in each group were comparable based on observed baseline characteristics. The propensity 
score model was derived as described previously and results are outlined in Supplementary 
Files Table S13 and Figure S4). Transition probabilities, costs, and QALYs were estimated 
after propensity score matching as described previously. Descriptive characteristics and annual 
transition probabilities for this subgroup are summarised in Supplementary Files Table S14 and 
Figure S5. 
 
Model validation 
The model structure, assumptions and input parameters were evaluated by clinical experts in 
Switzerland and were considered to reflect the natural history of the disease. Additional model 
checks included comparing life expectancy estimates from the model to Swiss life tables, which 
were found to be consistent. In addition, we performed quality control of inputted formulae and 
parameters. Finally, the plausibility of the model structure, inputs and results were compared to 
previous literature and are discussed.  
 
Ethical approval  
Ethical approval for the Swiss IBD Cohort Study was obtained from regional Swiss ethics 
committees where participants were enrolled [Commission d’éthique du Canton de 
Vaud/Protocol no. 33/06]. Written informed consent was obtained from all patients enrolled. 
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RESULTS 
Base case cost-effectiveness analysis 
The intervention strategy cost CHF86,562 (€77,464) and CHF43,808 (€39,204) more compared 
to the comparator over patients' lifetime from the health system and societal perspectives, 
respectively (Table 4). Despite incurring 0.1 more QALYs and CHF42,754 (€38,261) lower 
indirect costs, ICERs were above the WTP threshold from both perspectives (health system: 
CHF887,450/€794,180 per QALY; societal: CHF449,130/€402,000 per QALY). This was 
driven by higher costs of inducing and maintaining remission, and managing disease flares and 
strictures in the intervention strategy (Table 2). In addition, patients in the intervention group 
received biologic therapies for longer (Mean: 5 years, SD: 2.7) compared to biologic users in 
the comparator group (Mean: 3.5 years, SD: 2.7; p<0.001), contributing to higher health care 
costs. The QALY improvements reflected lower lifetime risks of disease flares and strictures, 
and higher probabilities of being in remission for patients in the intervention strategy 
(Supplementary Files Figure S3).  
[TABLE 4 HERE] 
Sensitivity analysis 
In one-way sensitivity analysis, the ICER from the health system perspective was most sensitive 
to changes in the utility value for strictures, the probability of disease flares in the intervention 
and comparator groups, and the probability of remission in the comparator group (Figure 2). 
The intervention was dominated (higher costs and lower QALYs) at the upper utility value for 
stricture and at the lower bound for the probability of remission in the intervention group. None 
of the parameters led to the ICER being cost-effective at a WTP of CHF100,000 per QALY 
when varied over its 95% CI. Similar results were found from the societal perspective 
(Supplementary Files Figure S6). The intervention was dominant (Cost∆: CHF-1621, QALY∆: 
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0.25) from the societal perspective when the probability of remission in the comparator group 
was reduced.  
[FIGURE 2 HERE] 
 
In PSA, the intervention strategy had a 0.10 and 0.25 probability of being below the WTP 
threshold from the health system and societal perspectives, respectively (Figure 3). The 
majority of simulations were clustered above the WTP threshold (Supplementary Files Figure 
S7).  
 [FIGURE 3 HERE] 
Scenario analyses 
ICERs were high when the model was evaluated over shorter time horizons and when using 
transition probabilities from Kaplan-Meier curves due to negligible differences in QALYs and 
high costs (Table 5). ICERs remained above the WTP threshold when using alternative 
transition probabilities and when utility estimates were varied for remission (CHF169,160 per 
QALY), fistula (CHF311,015 per QALY), and surgery (CHF1,160,000 per QALY) (Table 5). 
 
Assuming a 30% reduction in the price of biologics reduced the ICER from the health system 
perspective (CHF134,502 per QALY). Moreover, from the societal perspective, costs were 
lower and QALYs were higher (dominance) for the intervention group (Table 5).  
 
In the subgroup analysis considering only patients who were known to receive biologic 
treatments, early biologic initiation was cost saving and improved QALYs from the health 
system and societal perspectives. This was driven by lower health care costs for the early 
biologic initiation group and reduced risks of disease flares, fistulae and strictures over patient’s 
lifetime compared to the late biologic group (Supplementary Files Figure S5). 
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz169/5601202 by U
niversity of Zurich user on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz169 
 
[TABLE 5 HERE]  
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DISCUSSION 
Early treatment with biologic agents was associated with a significant cost burden and did not 
sufficiently improve health outcomes over a patient’s lifetime compared to similar patients who 
started biologics >2 years after diagnosis or who did not receive any biologic treatment. ICERs 
were considerably above CHF100,000 per QALY from the Swiss health system and societal 
perspectives. Early biologic users received biologic therapies for significantly longer compared 
to patients in the comparator group, contributing to high costs. These were not fully offset by 
the QALY improvements associated with a reduced lifetime risk of disease flares and strictures. 
Moreover, 50% of patients in the comparator group in the base case analysis did not progress 
to biologic therapies despite having similar observable baseline characteristics to those who 
received biologic treatments early (Supplementary Files Table S2). Amongst, non-biologic 
users we observed higher rates of surgery early on in the disease course, which could suggest a 
preference for surgical treatment instead of biologic treatment for some patients. Thus, 
widespread adoption of an early biologic treatment strategy could lead to overtreatment of these 
patients who may respond to alternative treatment approaches, incurring unnecessary costs. 
These results suggest that a rapid step-up treatment approach may be more appropriate from a 
cost-effectiveness perspective given the heterogeneity of disease presentation and prognosis.  
 
We identified several scenarios that might influence the cost-effectiveness of early biologic 
treatment. First, the comparator group had a higher burden of work absenteeism during active 
disease states. This indicates some societal gains from early biologic use although broader 
societal costs such as the need for invalidity benefits, and informal or formal care should also 
be considered. Moreover, a 30% reduction in the price of biologic therapies improved the ICER 
in favour of early biologic treatment, providing an opportunity for biosimilars, which were 
estimated to be significantly cheaper than their branded reference products in Europe39 40. The 
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz169/5601202 by U
niversity of Zurich user on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz169 
 
overall cost-effectiveness of biosimilars, however, will depend on how utilisation changes in 
response to price reductions with the potential for increased access as prices fall41. Finally, in 
the subgroup analysis considering only patients who were known to receive biologic treatments, 
starting treatment within 2 years of diagnosis (early) was associated with reduced costs and 
improved health outcomes compared to starting biologics >2 years after diagnosis (late). 
However, this subgroup analysis assumed perfect knowledge of which patients will require 
biologic treatment during the course of the disease and therefore would be appropriate to target 
for early biologic treatment. Thus, a better understanding of the phenotypic, genetic and 
serological characteristics of patients likely to benefit from and respond to aggressive biologic 
treatment approaches could help target early treatment strategies to the appropriate patients. 
Moreover, recent literature has shown that faster escalation of biologic treatments based on 
closer monitoring of known biomarkers of inflammation (such as C-reactive protein and faecal 
calprotectin) improved remission rates and was cost-effective compared to the conventional 
step-up approach where treatments were escalated based on clinical symptoms using disease 
activity scores42 43. Tight monitoring and rapid step-up treatment strategies will also be 
associated with increased costs due to frequent follow-up tests and consultations. Therefore, 
developing predictive models might help identify patients with a high likelihood of progressing 
to biologic treatment.  
 
Previous studies found that early compared to late biologic treatment was cost-saving and 
improved QALYs for moderate to severe CD over the lifetime in Canada15 and 5 years in Italy13. 
These studies were similar to our subgroup analysis since they included only patients who 
received biologic treatments. The results underscore the need to target early biologic treatment 
towards high-risk patients with poor outcomes. A systematic review showed that biologics were 
not cost-effective for maintenance of remission in several studies in Europe and North 
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America11. This may explain our results since patients remained on biologic therapies for 
several years and those in the intervention strategy received treatment for even longer. Clear 
guidelines about when to withdraw biologic treatments might help optimise disease 
management further from a clinical and cost perspective44.  
 
Our study differed from previous literature in the estimation of utilities, some of which used 
older sources of health-related quality of life data that might not reflect the benefits of current 
treatments11 15 45. Quality of life data was limited by missing information and a delay between 
the time of the event and response to questionnaires in the SIBDCS. We estimated higher mean 
utilities for patients with fistula, surgery and disease flares, and lower utilities for remission 
compared to previous literature45. This could be because patients in our study were recently 
diagnosed and might experience lower quality of life as they initially manage their diagnosis. 
Sensitivity and scenario analyses confirmed the importance of utility values on overall results. 
Future cost-effectiveness analyses will benefit from rigorous evaluation of patients’ utilities 
over the course of the disease. 
 
The main strength of this work is the use of long-term follow-up data reflecting real world 
clinical practice and treatment patterns. This allowed us to capture the dynamic and progressive 
nature of CD with health states to reflect the development of important disease complications. 
We used propensity score matching to reduce the risk of confounding and selection bias. 
Moreover, data used to parameterise the model were collected from the SIBDCS, reducing bias 
associated with pooling estimates from studies using heterogeneous methodologies and patient 
populations.  
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The model structure and parameterisation required assumptions, which may limit the 
generalisability of the results. Specifically, the risks of health outcomes were extrapolated using 
parametric time-to-event models. These predictions may have been affected by fewer patients 
in later years of follow-up. Long-term monitoring of health outcomes is required to evaluate 
the natural history of the disease as novel treatments are adopted. In addition, we could not 
evaluate transition specific probabilities or capture disease history due to small sample sizes 
and few event failures within these subgroups. However, preliminary analyses indicated no 
significant differences in results when alternative probabilities were used. Finally, some 
selection bias may have persisted despite propensity score matching due to unobserved factors. 
To manage this, we evaluated the impact of additional socio-demographic and clinical 
characteristics on the propensity score estimates based on feedback from clinical experts (e.g., 
education, employment status, diagnostic delay, and laboratory values). These did not 
significantly influence treatment assignment and were therefore excluded from the propensity 
score model. 
  
In conclusion, this study found that early biologic treatment was not cost-effective compared to 
biologic use more than 2 years after diagnosis or no biologic use in the Swiss CD population 
assuming a WTP threshold of CHF100,000 per QALY. However, there may exist a subgroup 
of patients for whom biologic treatment is necessary and where early initiation would be more 
cost-effective. In addition, price reductions from biosimilar agents would improve the cost-
effectiveness of early initiation. Future work should identify characteristics that help early 
stratification of patients that are more likely to benefit from biologic treatments in order to 
utilise these therapies effectively. 
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FIGURE LEGENDS 
Figure 1 Graphical representation of Crohn’s disease Markov model structure and movements 
between health states 
 
Figure 2 Tornado diagram showing the influence of varying each parameter individually on 
the ICER from the health system perspective; blue bars indicate ICER was reduced and red 
bars indicate ICER increased  
 
Figure 3 Cost-effectiveness acceptability curve from probabilistic sensitivity analysis after 
10’000 Monte Carlo simulations showing the probability that the intervention strategy is cost-
effective at different willingness to pay thresholds 
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TABLES AND FIGURES 
 
Table 1 Definition of health states in the Markov model 
Disease flares with no 
complications 
(disease flares) 
Active inflammation and/or initiation of new corticosteroid 
prescription and no indication of stricture, fistula or surgery at the 
same time 
Fistula 
Active perianal and non-perianal fistula observed through 
imaging scans and/or fistula-related surgeries (fistulectomy, 
fistula plug, fibrin glue instillation) 
Stricture Active stricture observed through imaging scans 
Intestinal resection 
surgery 
Intestinal resection surgeries including: ileal resection, small 
bowel resection, ileocecal resection, right & left colectomy, 
ileostomy and colostomy 
Remission 
Clinical remission defined based on a Crohn’s Disease Activity 
Index score <150 and the absence of disease flares, surgical 
interventions, fistula or stricture  
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Table 2 Mean total direct costs (CHF) per patient per year by health state for the comparator (late/no biologic use) and intervention (early 
biologic use) groups 
 
  
Disease 
duration 
(years) 
Disease flare Fistula Stricture Surgery Remission 
Late/no 
biologic 
Early 
biologic 
Late/no 
biologic 
Early 
biologic 
Late/no 
biologic 
Early 
biologic 
Late/no 
biologic 
Early 
biologic 
Late/no 
biologic 
Early 
biologic 
0 6,219 15,775 15,618 19,062 6,253 21,610 26,494 32,233 2,709 17,817 
1 6,846 15,548 16,520 19,114 6,789 20,603 27,517 32,854 3,112 17,043 
2 7,536 15,325 17,474 19,165 7,371 19,644 28,579 33,487 3,576 16,302 
3 8,296 15,105 18,484 19,217 8,004 18,729 29,682 34,132 4,109 15,593 
4 9,133 14,888 19,551 19,269 8,690 17,857 30,828 34,789 4,721 14,915 
5 10,054 14,675 20,680 19,321 9,435 17,025 32,017 35,459 5,425 14,266 
6 11,069 14,464 21,875 19,374 10,244 16,232 33,253 36,143 6,233 13,646 
7 12,185 14,256 23,138 19,426 11,123 15,476 34,537 36,839 7,162 13,053 
8* 13,414 14,052 24,474 19,479 12,077 14,756 35,870 37,548 8,230 12,485 
*Costs after 8 years were held constant for the remainder of the time that the model was run 
Average exchange rate in 2017:  CHF 1 = € 0.89; Source:  
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  https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-graph-
chf.en.html 
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Table 3 Parameters used in the base case analysis and ranges and distributions used to vary parameters in sensitivity and scenario analyses 
 Base case analysis 
One-way 
sensitivity 
analysis 
Probabilistic 
sensitivity analysis 
Direct and indirect costs 
Mean cost (CHF) 
per patient per 
year 
95% CI 
(lower, upper) 
Gamma 
distribution 
(Meana, SEǂ in 
CHF) 
Late/no biologic use (comparator): Disease 
flares 
Table 2 
8064, 13921 10,992 (2198) 
Late/no biologic use (comparator): Fistula 16435, 26594 21,515 (4303) 
Late/no biologic use (comparator): Stricture 7481, 12756 10,119 (2024) 
Late/no biologic use (comparator): Surgery 27291, 38227 32,759 (6552) 
Late/no biologic use (comparator): 
Remission 
5190, 7584 6387 (1277) 
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Late/no biologic use (comparator): Indirect 
costs active health states§ 
7019 5616, 8423* 7019 (1404) 
Late/no biologic use (comparator): Indirect 
costs  remission§ 
220 176, 264* 220 (44) 
Early biologic use (intervention): Disease 
flares 
Table 2 
13220, 16442 14,831 (2966) 
Early biologic use (intervention): Fistula 16159, 22415 19,287  (3857) 
Early biologic use (intervention): Stricture 15001, 20476 17,739 (3548) 
Early biologic use (intervention): Surgery 30697, 39417 35,057 (7011) 
Early biologic use (intervention): 
Remission 
14064, 15566 14,815 (2963) 
Early biologic use (intervention): Indirect 
costs active health states§ 
2560 2048; 3072* 2560 (512) 
Early biologic use (intervention): Indirect 
costs  remission§ 
730 584, 876* 730 (146) 
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Utilities 
Mean utility per 
patient per year 
95% CI 
Beta distribution 
(Mean, SE) 
Disease flares 0.66 0.63, 0.68 0.66 (0.14) 
Fistula 0.67 0.61, 0.74 0.67 (0.17) 
Stricture 0.68 0.64, 0.72 0.68 (0.13) 
Surgery 0.64 0.60, 0.68 0.64 (0.14) 
Remission 0.71 0.69, 0.73 0.71 (0.14) 
Annual transition probabilities 
Annual transition 
probability 
95% CI 
Beta distribution 
(Meanb, SEǂ) 
Late/no biologic use (comparator): Disease 
flares 
Supplementary 
Files Figure S3 
0.15, 0.35 0.25 (0.05) 
Late/no biologic use (comparator): Fistula 0.03, 0.08 0.06 (0.02) 
Late/no biologic use (comparator): Stricture 0.12, 0.28 0.20 (0.04) 
Late/no biologic use (comparator): Surgery 0.007, 0.02 0.01 (0.002) 
Late/no biologic use (comparator): 
Remission 
0.19, 0.45 0.32 (0.06) 
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Early biologic use (intervention): Disease 
flares 
0.11, 0.25 0.18 (0.04) 
Early biologic use (intervention): Fistula 0.01, 0.03 0.02 (0.004) 
Early biologic use (intervention): Stricture 0.03, 0.06 0.05 (0.01) 
Early biologic use (intervention): Surgery 0.01, 0.03 0.02 (0.004) 
Early biologic use (intervention): 
Remission 
0.22, 0.51 0.36 (0.07) 
Mortality rates 
Supplementary 
Files Table S6 
  
Other parameters    
Crohn’s disease standardised mortality 
rate27  
1.39 1.3, 1.49 N/A 
ǂStandard deviation (SD) defined as 20% of mean 
§Mean indirect costs were adjusted for the labour participation rates in Switzerland (see Supplementary Files 
Table S7) 
aThe mean cost value used in PSA reflect the mean cost averaged over disease duration 
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bThe mean transition probability per health state was calculated by averaging annual probabilities over 50 
years  
*Mean ± 20% used because 95% CI was negative 
Average exchange rate in 2017:  CHF 1 = € 0.89; Source:  
https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-
graph-chf.en.html 
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Late/no biologic use 
(comparator) 
Early biologic use (intervention) 
Incremental 
difference  
 Undiscounted Discounted Undiscounted Discounted Discounted 
Direct costs 
CHF 520,826  
(€  466,087) 
CHF 270,667 
(€ 242,220) 
CHF 645,439 
(€ 577,603) 
CHF 357,229 
(€ 319,684) 
CHF 86,562 
(€ 77,464) 
Indirect costs 
CHF 112,599 
(€ 100,765) 
CHF 70,132 
(€ 62,761) 
CHF 42,015 
(€ 37,599) 
CHF 27,379 
(€ 24,501) 
CHF -42,754 
(€ -38,261) 
Total costs 
CHF 633,425 
(€ 566,852) 
340,799 
(€ 304,981) 
CHF 687,455 
(€ 615,203) 
CHF 384,607 
(€ 344,185) 
CHF 43,808 
€ 39,204 
Quality-adjusted life years 
(QALYs) 
30.79 16.75 31.01 16.84 0.10 
Incremental cost-effectiveness ratios (costs per QALY) 
Swiss health system perspective 
CHF 887,450 
(€ 794'180) 
Societal perspective 
CHF 449,130 
(€ 401'926) 
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Table 4 Cost-effectiveness results for the base case analysis 
 
 
  
Average exchange rate in 2017:  CHF 1 = € 0.89; Source:  https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-
graph-chf.en.html 
CHF: Swiss francs 
Euros (€) 
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Table 5 Results of scenario analyses used to test the impact of methodological uncertainty on base case results 
Description of scenario  
Incremental 
direct costs 
(CHF) 
Incremental 
total costs 
(CHF) 
Incremental 
QALYs 
ICER in CHF 
Health system 
perspective 
ICER in 
CHF 
Societal 
perspective 
Base case analysis 86,562 43,808 0.10 887,450 449,130 
Discount rate: 2% 96,114 46,192 0.13 755,770 363,216 
Discount rate: 5% 72,844 40,427 0.06 1,225,429 680,083 
Time horizon: 1 year 8211 4633 -0.0001 
Intervention 
dominateda 
Intervention 
dominateda 
Time horizon: 10 years 59,229 44,917 0.002 >35 million >30 million 
Subgroup analysis: Biologic users only (see Supplementary Files 
Table S14) 
-24,636 -64,097 0.19 
Intervention 
dominantb 
Intervention 
dominantb 
Transition probabilities      
Probability of remission parameterised using the complement of 
row probabilities 
93,288 40,559 0.15 615,409 267,564 
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Transition probability from remission to any active disease 
derived from time-to-event model for the subgroup of the 
population who experienced at least 1 remission event 
88,790 24,831 0.12 744,585 208,235 
Transition probability from a given active state to remission 
derived from time-to-event model for the subgroup of patients 
who experienced at least 1 of the relevant active events (disease 
flare, surgery, stricture, and fistula) 
83,874 17,750 0.10 808,273 171,051 
Transition probabilities derived from Kaplan-Meier curves for a 
time horizon of 10 years; removing the need for extrapolation of 
health outcomes 
59,487 44,072 0.003 17,527,352 12,985,400 
Utilities      
Fistula: 0.4* 86,562 43,808 0.28 311,014 81,213 
Remission: 0.83* 86,562 43,808 0.51 169,159 44,172 
Disease flares: 0.62ǂ 86,562 43,808 0.11 821,207 214,438 
Surgery: 0.54ǂ 86,562 43,808 0.07 1,157,638 302,288 
Costs      
D
ow
nloaded from
 https://academ
ic.oup.com
/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjz169/5601202 by U
niversity of Zurich user on 05 D
ecem
ber 2019
Ac
ce
pte
d M
an
us
cri
pt
Manuscript Doi: 10.1093/ecco-jcc/jjz169 
 
Mean overall annual per patient direct costs fixed for each health 
state 
142,383 78,425 0.10 1,459,745 804,032 
Assume price of biologic agents reduced by 30%§ 13,119 -29,634 0.10 134'502 
Intervention 
dominantb 
*Lindsay J, et al. (2008)45 
ǂGregor et al. (1997)46 
§IMS Institute for healthcare informatics (2016)38 
aDominated: Intervention had higher costs and lower QALYs 
bDominant: Intervention had lower costs and higher QALYs 
Average exchange rate in 2017:  CHF 1 = € 0.89; Source:  
https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro
_reference_exchange_rates/html/eurofxref-graph-chf.en.html 
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Figure 1 Graphical representation of Crohn’s disease Markov model structure and movements 
between health states 
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Figure 2 Tornado diagram showing the influence of varying each parameter individually on 
the ICER from the health system perspective; blue bars indicate ICER was reduced and red 
bars indicate ICER increased  
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 Figure 3 Cost-effectiveness acceptability curve from probabilistic sensitivity analysis after 
10’000 Monte Carlo simulations showing the probability that the intervention strategy is cost-
effective at different willingness to pay thresholds
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